Table 7. Joint-effects survival analysis of PLCE1 and serum AFP levels in HBV-related HCC patients from GSE14520.
| Group | PLCE1 level | AFP (ng/ml) | Patients (n=214) φ | No. of events (%) | MST (months) | Adjusted HR(95% CI) | AdjustedP§ |
|---|---|---|---|---|---|---|---|
| DFS | |||||||
| i | High | >300 | 47 | 33 (70.2) | 21 | 1 | |
| ii | High | ≤300 | 60 | 36 (60.0) | 41 | 0.777(0.476-1.266) | 0.31 |
| iii | Low | >300 | 49 | 22 (44.9) | 59 | 0.459(0.263-0.803) | 0.006 |
| iiii | Low | ≤300 | 58 | 29 (50.0) | 51 | 0.570(0.335-0.968) | 0.038 |
| OS | |||||||
| a | High | >300 | 47 | 28 (59.6) | 26 | 1 | |
| b | High | ≤300 | 60 | 25 (41.7) | NA | 0.709(0.404-1.246) | 0.232 |
| c | Low | >300 | 49 | 15 (30.6) | NA | 0.384(0.201-0.734) | 0.004 |
| d | Low | ≤300 | 58 | 15 (25.9) | NA | 0.347(0.180-0.670) | 0.002 |
Notes: φ Information of AFP was unavailable in 4 patients; § Adjustment for age, gender, cirrhosis, BCLC stage, serum AFP levels; DFS, disease-free survival; OS, overall survival; MST, median survival time; HR, hazard ratio; CI, confidence interval.